LONDON – Autifony Therapeutics Ltd. has started Phase I development of AUT00063, its treatment for age-related hearing loss and tinnitus, and raised a further £5.5 million (US$8.5 million) to take that lead program through to clinical proof of concept. Read More

LONDON – The identification of the exact molecule on the insides of blood vessels to which malaria parasites stick will allow an immediate start on work to develop vaccines and new therapies for severe forms of malaria, the scientists who made the discovery predicted. Read More

LONDON – A £9.3 million (US$14.43 million) publicly funded ubiquitin research program has overcome difficulties in drugging those key protein recycling targets, leading to the formation of UB Pharma Ltd., which has now set out to raise £4 million to £6 million to take the lead candidates through to the clinic. Read More

SHANGHAI – Beigene Co. Ltd. has licensed a second-generation BRAF inhibitor as a promising preclinical oncology drug to Merck KGaA, of Darmstadt, Germany, for the treatment of melanoma, colorectal cancer and other cancers. Read More

SHANGHAI, China – While the presidents from the U.S. and China have met in a summit to address human rights and cyber-attack issues, it's become clear that U.S. biopharmaceutical firms have not been immune to targeted hacking out of China. These efforts may have yielded valuable data from clinical trials or drug registration applications. Read More

TAIPEI, Taiwan – It's been a long wait, but Taiwan's drug development industry might just be coming of age. While the island nation is still awaiting its first home-grown innovator drug, a number of companies are almost there. Read More

• Santhera Pharmaceuticals AG, of Liestal, Switzerland, said it obtained an exclusive license from the National Institutes of Health (NIH) to rights on a patent granted in the U.S. for the use of idebenone for the treatment of primary aggressive multiple sclerosis. Read More